Hyperbaric Oxygen Therapy
HBOT is a medical oxygen-pressure intervention, not a generic wellness oxygen upgrade. Hard-chamber protocols around 2.0-2.4 ATA have strong indication-specific medical use and smaller off-label signals in cognitive aging, chronic post-stroke deficits, fibromyalgia, selected wounds, and some neuro-recovery contexts. Soft-chamber 1.3 ATA does not match the pressure tier used in the main cognitive-aging, fibromyalgia, or post-stroke studies. The 2025 HOT-LoCO trial found 10 sessions were not superior to sham for long COVID primary outcomes (Kjellberg 2025), so post-viral claims need heavier skepticism.
Hyperbaric Oxygen Therapy scored 5.2 / 10 (⚖️ Neutral) on the BioHarmony scale as a Device / Technology.
What It Is
Hyperbaric oxygen therapy (HBOT) exposes the body to high oxygen availability under pressure, usually inside a rigid medical chamber at 2.0-2.4 ATA for clinical protocols. The combination of pressure and oxygen increases dissolved oxygen in plasma, changes tissue oxygen gradients, and can support angiogenesis, wound repair, inflammation modulation, and neurological recovery in selected contexts. This is why HBOT belongs first in medical categories like decompression sickness, carbon monoxide poisoning, delayed radiation injury, selected hard-to-heal wounds, compromised grafts/flaps, and refractory osteomyelitis rather than in generic wellness.
The consumer confusion comes from collapsing pressure tiers. Hard-chamber protocols like Hadanny 2020, Efrati 2015, and Efrati 2013 used around 2.0 ATA and long protocols. Soft chambers at 1.3-1.5 ATA may still feel meaningful and may be biologically active, but they do not match the pressure tier behind the main cognitive-aging, fibromyalgia, or post-stroke evidence. That mismatch is the central practical risk in home-chamber marketing.
The v1.0 update is more conservative on long COVID and wellness claims. Hadanny 2024 supports longer-term persistence after a prior post-COVID protocol, but Kjellberg 2025 found 10 HBOT sessions were not superior to sham on primary long-COVID outcomes at 13 weeks. Meanwhile Yang 2024 strengthens adjunctive wound-care interest, Dokmak 2024 suggests a possible fistulizing Crohn's signal, and Li 2024 argues against routine acute-stroke use.
Terminology
For a clinical indication cross-reference see the UHMS indication list and FDA consumer safety framing on hyperbaric oxygen therapy.
- HBOT: Hyperbaric Oxygen Therapy. Medical treatment delivering oxygen under pressure inside a chamber.
- mHBOT: Mild Hyperbaric Oxygen Therapy. Usually soft-chamber exposure around 1.3-1.5 ATA; not interchangeable with 2.0-2.4 ATA hard-chamber evidence.
- ATA: Atmospheres Absolute. Pressure unit including atmospheric pressure. Sea level is about 1.0 ATA.
- UHMS: Undersea and Hyperbaric Medical Society. Professional society defining accepted indications and practice standards.
- Hard chamber: Rigid monoplace or multiplace chamber that can reach medical pressure tiers such as 2.0-2.4 ATA.
- Soft chamber: Inflatable chamber, usually limited to lower pressure and often sold for home or wellness use.
- Air breaks: Scheduled breathing of normal air during higher-oxygen protocols to reduce oxygen-toxicity risk and create intermittent oxygen signaling.
- HIF-1 alpha: Hypoxia-Inducible Factor 1-alpha. Transcription factor involved in oxygen-gradient signaling, angiogenesis, and repair pathways.
- eNOS: Endothelial Nitric Oxide Synthase. Enzyme involved in vascular signaling and progenitor-cell mobilization.
- VEGF: Vascular Endothelial Growth Factor. Angiogenic protein relevant to wound repair and vascular remodeling.
- DCS: Decompression Sickness. Diving or pressure-change injury where HBOT is a core treatment.
- DFU: Diabetic Foot Ulcer. A wound-care indication where HBOT may be used selectively, though evidence and guideline positions vary.
- HOT-LoCO: 2025 long-COVID sham-controlled trial by Kjellberg et al. that found 10 HBOT sessions were not superior to sham on primary outcomes.
- Harch protocol: TBI-oriented protocol often discussed around 1.5 ATA for 40 sessions; remains controversial in mainstream guideline interpretation.
- Aviv-style protocol: Commercial 60-session hard-chamber model associated with Efrati/Hadanny cognitive-aging and post-COVID research.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 4 routes and 6 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Hard monoplace chamber | Single-person rigid chamber delivering high oxygen exposure at clinical pressure | Typically 2.0-2.4 ATA for 90-120 minutes; protocols vary by indication | 2.0 ATA for 90 minutes, 5 days/week, 40-60 sessions for off-label cognitive, longevity, post-viral, or recovery programs |
| Hard multiplace chamber | Room-sized chamber with patients breathing oxygen through mask, hood, or tube | Typically 2.0-2.8 ATA depending on indication | Rare in consumer wellness use; generally hospital or specialty-clinic setting |
| Soft mild HBOT chamber | Inflatable or portable chamber usually limited to 1.3-1.5 ATA | FDA-cleared use is acute mountain sickness transport context, not the main off-label cognitive-aging protocols | 60-90 minutes, 3-7x/week, often paired with oxygen concentrator |
| Emergency recompression | Clinical HBOT for decompression sickness, arterial gas embolism, carbon monoxide poisoning, or severe acute indications | Protocol-specific; often higher pressure and urgent treatment windows | Not appropriate for self-directed use |
Protocols
UHMS-accepted medical indication protocol Clinical
- Dose
- 2.0-2.4 ATA for 90-120 minutes
- Frequency
- Usually daily or near-daily during active treatment
- Duration
- Often 20-40 sessions; emergency protocols vary
Best evidence-to-risk ratio. Indications include decompression sickness, carbon monoxide poisoning, selected problem wounds, delayed radiation injury, refractory osteomyelitis, compromised grafts/flaps, and sudden sensorineural hearing loss.
Cognitive aging hard-chamber protocol Mixed
- Dose
- 2.0 ATA for 90 minutes with air breaks
- Frequency
- 5x/week
- Duration
- 60 sessions over roughly 12 weeks
Modeled on [Hadanny 2020](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377835/). Best fit is older adults with documented cognitive complaints, not young healthy users seeking a general productivity upgrade.
Fibromyalgia protocol Clinical
- Dose
- 2.0 ATA for 90 minutes
- Frequency
- 5x/week
- Duration
- 40 sessions in the [Efrati 2015](https://pubmed.ncbi.nlm.nih.gov/26010952/) prospective crossover trial
Favorable but small evidence base. Best considered as adjunctive care when standard pain, sleep, nervous-system, and metabolic interventions are already addressed.
Chronic post-stroke protocol Clinical
- Dose
- 2.0 ATA for 90 minutes
- Frequency
- 5x/week
- Duration
- 40 sessions in [Efrati 2013](https://pubmed.ncbi.nlm.nih.gov/23335971/)
Studied in chronic-phase post-stroke patients, not acute ischemic stroke. [Li 2024](https://link.springer.com/article/10.1186/s12883-024-03555-W) did not support routine HBOT for acute ischemic stroke outcomes.
Long COVID protocol Mixed
- Dose
- 2.0-2.4 ATA depending on protocol
- Frequency
- Variable; positive Efrati/Hadanny cluster used longer protocols, HOT-LoCO used 10 sessions
- Duration
- 10-60 sessions depending on study
Now contested. [Hadanny 2024](https://pubmed.ncbi.nlm.nih.gov/38360929/) reported longer-term persistence after a prior positive protocol, but [Kjellberg 2025](https://pubmed.ncbi.nlm.nih.gov/40228859/) found 10 sessions were not superior to sham at 13 weeks.
Home soft-chamber wellness protocol Anecdotal
- Dose
- 1.3-1.5 ATA for 60-90 minutes
- Frequency
- 3-7x/week
- Duration
- Open-ended
Most vulnerable to overclaiming. Does not reproduce the pressure tier used in the main hard-chamber cognitive-aging, fibromyalgia, or post-stroke evidence.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 2.82
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 4.1 | 1.025 | |
| Breadth of Benefits | 15% | 4.4 | 0.660 | |
| Evidence Quality | 25% | 3.8 | 0.950 | |
| Speed of Onset | 10% | 2.6 | 0.260 | |
| Durability | 10% | 3.2 | 0.320 | |
| Bioindividuality Upside | 15% | 4.0 | 0.600 | |
| Total | 3.815 |
Upside Rationale
Hyperbaric Oxygen Therapy offers measurable benefit when the pressure level matches a clinically validated indication, which drives the upside score across efficacy, breadth, and evidence dimensions. The therapy's strongest points stem from its ability to accelerate tissue oxygenation, supporting wound repair and reducing inflammation in hard-chamber protocols that reach 2.0-2.4 ATA. Clinical reviews show improved healing rates when combined with negative-pressure wound therapy Yang 2024, and meta-analyses report favorable response in fistulizing Crohn's disease Dokmak 2024, highlighting genuine breadth beyond classic decompression uses. Neuro-recovery signals appear in chronic post-stroke and fibromyalgia trials, though larger confirmatory studies remain pending. These positive signals are tempered by neutral outcomes in recent long-COVID trials Kjellberg 2025, reminding readers that benefit hinges on indication-specific dosing. Overall, Hyperbaric Oxygen Therapy's upside reflects a focused therapeutic niche rather than a universal wellness fix.
Efficacy (3.7/5.0). HBOT efficacy stratifies sharply by pressure tier and indication. For accepted medical indications, HBOT can be decisive. For off-label longevity and consumer cognition, the evidence is much less settled. Efrati 2015 supports fibromyalgia benefit in a prospective active-control crossover trial; Efrati 2013 supports chronic post-stroke neuroplasticity; Hadanny 2020 supports a hard-chamber cognitive-aging signal in older adults. But Kjellberg 2025 was negative/neutral for 10-session long-COVID HBOT versus sham, and Li 2024 did not support routine acute-stroke use. Net: strong when indication-matched, easy to overstate when sold as broad wellness.
Breadth of benefits (4.2/5.0). HBOT has unusually broad medical breadth: decompression sickness, carbon monoxide poisoning, arterial gas embolism, delayed radiation injury, selected wound care, compromised grafts/flaps, refractory osteomyelitis, sudden sensorineural hearing loss, and severe infection contexts. Off-label breadth adds chronic post-stroke deficits, fibromyalgia, cognitive aging, post-COVID condition, TBI, Crohn's fistulas, and recovery. The breadth is real, but it is not uniform. Dokmak 2024 and Yang 2024 broaden the modern surveillance surface without turning every claim into a mature indication.
Evidence quality (3.5/5.0). Evidence quality is heterogeneous. Several medical indications have society support and long clinical use, but consumer-facing claims rely on smaller trials, single-center clusters, adjunctive designs, or commercially adjacent protocols. Kjellberg 2025 is important because it is sham-controlled and directly weakens short-course long-COVID claims. Shahid 2025 and Li 2025 keep neuro-recovery interest alive but are not enough to override conservative authority positions. FDA and UHMS support defined medical uses, not broad anti-aging or wellness positioning.
Speed of onset (2.6/5.0). Speed depends on endpoint. Decompression sickness and carbon monoxide poisoning are acute medical domains. Wound-care benefits usually require weeks. Fibromyalgia, chronic post-stroke, cognitive aging, and post-COVID protocols generally require 40-60 sessions before reassessment. A standard consumer hard-chamber protocol can mean 8-12 weeks before the user knows whether it worked. That makes HBOT slower and more effort-heavy than most supplements, recovery tools, or behavioral interventions.
Durability (3.0/5.0). Durability is mid-range. Structural wound repair and vascular remodeling may persist, while subjective fatigue, pain, cognition, and recovery gains may fade without retreatment. Hadanny 2024 supports persistence after a prior post-COVID protocol, but that does not generalize to every indication or to short-course soft-chamber use. HBOT is not a learned skill, and most off-label protocols depend on a large pulse of repeated exposure rather than a permanent state change.
Bioindividuality (3.8/5.0). HBOT is highly phenotype-dependent. Older adults with documented cognitive complaints are not the same as healthy younger biohackers. Diabetic wound patients with adequate perfusion are not the same as patients with critical limb ischemia. Ear and sinus anatomy, claustrophobia, pressure tolerance, medication history, pulmonary status, vascular reserve, and inflammation state all gate usability and benefit. This is a feature in medicine because patient selection improves the signal; it is a liability in wellness marketing because the average buyer often lacks a precise target.
Downside contribution: 2.61 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 4.0 | 1.200 | |
| Side Effect Profile | 15% | 3.1 | 0.465 | |
| Financial Cost | 5% | 4.7 | 0.235 | |
| Time/Effort Burden | 5% | 4.3 | 0.215 | |
| Opportunity Cost | 5% | 3.0 | 0.150 | |
| Dependency / Withdrawal | 15% | 1.5 | 0.225 | |
| Reversibility | 25% | 2.0 | 0.500 | |
| Total | 2.990 | |||
| Harm subtotal × 1.4 | 3.346 | |||
| Opportunity subtotal × 1.0 | 0.600 | |||
| Combined downside | 3.946 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 2.606 |
Downside Rationale
Hyperbaric Oxygen Therapy carries a steep trade-off between potential benefit and measurable burden, so users should weigh cost, time, and safety before committing. The financial outlay for a medically relevant protocol can exceed $10,000, far higher than most self-administered biohacks, and insurance rarely covers off-label uses. Session schedules often demand daily 60-minute exposures over weeks, creating a sizeable time commitment that can displace training, work, or family activities. Safety concerns include fire risk in oxygen-rich chambers, oxygen-toxicity seizures, and barotrauma, especially when screening is lax in commercial wellness settings. Recent trials such as the HOT-LoCO study found no advantage over sham for long-COVID outcomes, underscoring the uncertain return on investment for many experimental indications Kjellberg 2025. Users with pulmonary disease, uncontrolled diabetes, or seizure history should approach Hyperbaric Oxygen Therapy with particular caution.
Safety risk (4.0/5.0). Worst-case safety risk is materially higher than most consumer interventions. Serious events are rare in accredited medical settings, but HBOT has intrinsic hazards: chamber fire risk in oxygen-enriched environments, oxygen toxicity seizure, untreated pneumothorax converting under pressure, severe pulmonary risk in relevant chemotherapy exposure, and dangerous use in poorly screened pulmonary disease. FDA safety messaging and UHMS facility standards exist for a reason. Wellness clinics without serious fire prevention, grounding, screening, and emergency protocols change the risk profile.
Side effect profile (2.8/5.0). Common non-severe problems include ear barotrauma, sinus pressure, temporary myopia, fatigue, claustrophobia, headache, and difficulty equalizing. Risk rises at higher pressure tiers, which are also where many off-label protocols sit. Upper-respiratory infection, recent ear/sinus surgery, COPD bullae, anxiety in monoplace chambers, and glucose instability in diabetes all raise practical friction. Side effects are usually manageable, but the profile is far more active than red light, creatine, sauna, or basic breathwork.
Financial cost (4.5/5.0). Hard-chamber sessions commonly cost about $150-300 in the US, making a 60-session protocol roughly $9,000-18,000 before diagnostics, travel, or opportunity cost. Premium programs can exceed $50,000. Home soft chambers can cost $4,000-20,000 but do not match the hard-chamber evidence tier. Insurance typically follows recognized medical indications. For wellness, cognition, long COVID, or anti-aging, the user is often paying out of pocket for a protocol with uncertain marginal return.
Time / effort burden (4.0/5.0). HBOT is one of the highest-effort interventions in the archive. A common off-label protocol means 60-90 minutes per session, 5 days per week, for 8-12 weeks, plus travel, intake, ear equalization, chamber time, air breaks, and post-session recovery. Even motivated users can lose an entire season of training, work blocks, or family time to a full course. The effort score stays high even when the protocol is medically justified.
Opportunity cost (2.5/5.0). Opportunity cost depends on indication. For decompression sickness, carbon monoxide poisoning, delayed radiation injury, or a serious wound, alternatives may be worse and the opportunity cost is low. For a healthy user buying cognitive aging, post-viral, or longevity sessions, the same money and hours may buy more reliable gains through sleep repair, aerobic capacity, strength training, blood-pressure control, glucose control, nutrition, and targeted medical workups. Kjellberg 2025 makes that tradeoff harder for short-course long-COVID use.
Dependency / withdrawal (1.5/5.0). HBOT has no withdrawal syndrome, addiction pattern, receptor downregulation concern, or scheduled-substance issue. Stopping simply removes the repeated pressure/oxygen stimulus. Some benefits may fade, especially subjective energy, pain, and cognitive effects, but this is return toward baseline rather than withdrawal. The dependency score is low because the intervention does not create compulsive use or acute rebound physiology.
Reversibility (2.0/5.0). Most HBOT effects are reversible or naturally fade after cessation. The exceptions are why the score is not lower: cataract acceleration after extended exposure, rare permanent ear injury from severe barotrauma, pulmonary fibrosis risk in vulnerable drug-exposure contexts, and the very rare severe chamber accident. In properly screened users, the intervention is usually reversible. In poorly screened users, the tail risk is not zero.
Verdict
Hyperbaric Oxygen Therapy delivers oxygen at 2.0-2.4 ATA and shows the strongest evidence for medically indicated conditions such as decompression illness, carbon monoxide poisoning, and certain hard-to-heal wounds, while off-label benefits appear modest for chronic post-stroke recovery, fibromyalgia, and age-related cognitive complaints; the evidence does not support routine use for acute ischemic stroke or long-COVID symptom relief. Trials like the 2025 HOT-LoCO study found no advantage over sham for long-COVID outcomes, highlighting the need for caution in that indication (Kjellberg 2025). Meta-analyses of wound-care trials report improved healing when hyperbaric oxygen is added to negative-pressure therapy, suggesting a role for selected chronic ulcers (Yang 2024). Neuro-rehabilitation data remain mixed, with small studies hinting at cognitive gains but larger, higher-quality trials still required to confirm those signals.
✅ Best for: Patients with UHMS-accepted indications first: decompression sickness, carbon monoxide poisoning, arterial gas embolism, selected diabetic foot ulcers, delayed radiation injury, refractory osteomyelitis, compromised grafts/flaps, sudden sensorineural hearing loss, intracranial abscess, severe anemia, and other established clinical uses. Off-label, the best fit is older adults with documented cognitive complaints considering a hard-chamber protocol like Hadanny 2020, chronic post-stroke patients per Efrati 2013, fibromyalgia patients per Efrati 2015, selected wound-care patients where Yang 2024 is relevant, and serious experimenters who can afford a full protocol without displacing higher-confidence health basics.
❌ Avoid if: You have untreated pneumothorax, relevant bleomycin exposure without specialist clearance, active doxorubicin/cisplatin/disulfiram exposure, severe COPD with bullae, uncontrolled diabetes, current fever or upper-respiratory infection, recent ear/sinus surgery without ENT clearance, severe claustrophobia, or elective pregnancy use. Avoid wellness clinics that cannot clearly explain fire prevention, screening, oxygen protocols, emergency procedures, and pressure tier. Avoid soft-chamber 1.3 ATA if you expect the hard-chamber outcomes reported in cognitive-aging, fibromyalgia, or chronic post-stroke studies. Avoid long-COVID packages marketed as settled science after Kjellberg 2025.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Wound Healing: 7.8/10
Score: 7.8/10The wound-healing use case for Hyperbaric Oxygen Therapy scores 7.8/10, reflecting the pooled effect size reported in a meta-analysis of 15 studies that found adjunctive HBOT improves healing rates when combined with negative-pressure wound therapy Yang 2024. Hyperbaric Oxygen Therapy is most often evaluated as an adjunct to standard wound care, where it appears to increase oxygen delivery to hypoxic tissue and support fibroblast activity. The evidence tier remains moderate because study designs vary and comparators are heterogeneous, preventing drug-grade certainty. Responders in higher-quality trials note faster granulation and reduced infection risk, but larger, blinded RCTs are still needed to confirm these findings.
Anti-Inflammatory: 5.9/10
Score: 5.9/10The anti-inflammatory rating for Hyperbaric Oxygen Therapy is 5.9/10, reflecting results from a phase II randomised trial of 80 long-COVID patients Kjellberg 2025. Hyperbaric Oxygen Therapy is proposed to modulate inflammation in wounds, fibromyalgia, and neuro-recovery, but human endpoint certainty varies across conditions. Systematic reviews show modest benefits for Crohn's disease and hard-to-heal wounds, yet the underlying trials carry high risk of bias and low methodological confidence Dokmak 2024; Yang 2024. Overall, the evidence tier for anti-inflammatory effects remains low to moderate, suggesting that responders may experience some benefit while non-responders see limited change.
Mitochondrial: 5.6/10
Score: 5.6/10The evidence gives Hyperbaric Oxygen Therapy a mitochondrial use-case score of 5.6/10, based on a phase-II trial of ten sessions in long-COVID patients that showed no significant functional gain Kjellberg 2025. Hyperbaric Oxygen Therapy can raise tissue oxygen levels, which may support mitochondrial respiration under stress, but the effect is not uniform across conditions. Small systematic reviews suggest modest neurocognitive benefits after brain injury, yet methodological confidence remains low Shahid 2025. Trials in acute stroke and chronic wound healing show mixed outcomes, highlighting that any mitochondrial advantage depends on the underlying pathology and treatment protocol. Overall, the evidence tier is moderate, and responders appear to be condition-specific.
Recovery / Repair: 5.5/10
Score: 5.5/10The evidence gives Hyperbaric Oxygen Therapy a recovery-repair score of 5.5/10, based on a meta-analysis of 15 wound-care trials showing modest healing benefits Yang 2024. Hyperbaric Oxygen Therapy is thought to boost tissue oxygen levels, which can accelerate cellular repair and reduce inflammation, a mechanism that underlies its use in chronic wounds and radiation injury. However, most trials involve patients with medical conditions, and data from healthy athletes remain sparse, limiting confidence in direct performance gains. Cost, session time, and the need for a pressurized chamber also lower its practical appeal for routine recovery-repair use. Overall, the tier-II evidence supports modest effects but suggests cautious expectations.
Hearing / Auditory: 6.8/10
Score: 6.8/10Sudden sensorineural hearing loss is a stronger non-wound indication for HBOT, especially as adjunctive acute therapy with steroids. Moghib 2025 supports adjunctive benefit in selected acute windows. This deserves a high subrating, caveated by timing, diagnosis, and ENT collaboration. Chronic hearing loss outside the acute window does not inherit the same evidence. Patients should pursue evaluation quickly because the treatment window is short and the steroid-plus-HBOT pathway requires coordinated care.
Injury Recovery: 6.5/10
Score: 6.5/10Crush injury, acute traumatic ischemia, compromised grafts, burns, radiation injury, and chronic wounds justify a strong supervised injury-recovery score. UHMS 2025 outlines these indications. Score above neutral because the injury-recovery use case is one of the most defensible HBOT indications. Healthy athletes should not extrapolate from medical injury-rescue contexts to routine training-recovery use. Pressure tier, session count, and supervising clinician all matter. Soft-chamber wellness protocols do not match the injury-recovery evidence.
Bone / Joint Health: 6.4/10
Score: 6.4/10Refractory osteomyelitis, osteoradionecrosis, and avascular necrosis are recognized indications per UHMS 2025. This makes bone-joint one of the better medical-adjacent slugs for HBOT scoring. Score higher because the framing is clinician-supervised disease care, not casual joint wellness. Athletes and healthy users should not extrapolate to general joint maintenance. Bone necrosis and post-radiation jaw or pelvic injury are the use cases that justify a strong score here.
Cognition / Focus: 6.4/10
Score: 6.4/10Older-adult cognition trials and chronic neurorehab studies justify a meaningful score. Hadanny 2020 reports gains in attention, processing speed, and executive function after sixty hard-chamber sessions. The effect is protocol-heavy and not proven for young healthy productivity users. Score above neutral but below strong-recommend because the evidence ecosystem is narrow. Soft-chamber wellness protocols at 1.3 ATA do not inherit Hadanny 2020 evidence. The cognitive-aging use case requires hard-chamber pressure tier.
Neuroplasticity: 6.2/10
Score: 6.2/10Chronic stroke, TBI, and cognitive-aging studies repeatedly invoke perfusion and neuroplasticity signals. Efrati 2013 reports neurological improvement with brain perfusion changes in chronic post-stroke patients. Score above neutral with the caveat that most evidence comes from forty to sixty hard-chamber sessions. Healthy users should not expect generalized neuroplasticity gains from short or low-pressure exposure. Pressure tier and session count both matter for the neuroplasticity use case.
Memory: 5.9/10
Score: 5.9/10Memory support is plausible via cognitive-aging and post-stroke literature. Hadanny 2020 shows improvements clustered in attention, processing speed, and executive function rather than pure memory. Boussi-Gross 2014 reports memory improvement in chronic mild TBI patients after hard-chamber protocols. Score above neutral but caveat that memory was not the strongest endpoint in the cognitive-aging ecosystem. Healthy young users should not expect generalized memory gains from short hyperbaric exposure.
Geriatric / Aging Population: 5.9/10
Score: 5.9/10Older-adult cognition, telomere work, wound care, and radiation-injury data make geriatric one of the more relevant off-label slugs. Hadanny 2020 supports cognitive gains in adults age 64 and older after hard-chamber protocols. Hachmo 2020 supports immunosenescence reductions in the same population. Score above neutral. The geriatric use case remains expensive and protocol-heavy. Wealthy older adults with documented cognitive or wound concerns are the most defensible target population.
Dental / Oral Health: 5.8/10
Score: 5.8/10Dental and oral relevance is strongest for osteoradionecrosis, mandibular radiation injury, and surgical complication reduction in irradiated tissue. Bennett 2023 supports adjunctive use for late radiation injury contexts. This is not a general oral-health biohack. Oncology dental teams use hyperbaric protocols around tooth extraction in irradiated jaws. Score above neutral because the indication-specific dental-oral use case is real. The wellness framing does not generalize to gum health claims.
Telomere / DNA Repair: 5.8/10
Score: 5.8/10The telomere-length signal is one of the better longevity-specific findings for HBOT. Hachmo 2020 reports immune-cell telomere lengthening after sixty hard-chamber sessions in older adults. The trial is small and not a disease-outcome study. Score above neutral but below strong-recommend. Independent replication is missing. Wealthy older adults with documented cognitive complaints remain the most defensible target population. Telomere outcomes do not yet predict mortality or disease prevention in this cohort.
Traumatic Brain Injury: 5.8/10
Score: 5.8/10TBI evidence is mixed but meaningful for chronic persistent post-concussion protocols. Boussi-Gross 2013 reports cognitive and quality-of-life improvements after forty sessions. Hadanny 2018 supports a retrospective cohort. Wolf 2012 prevents a high score because a sham-controlled military trial did not separate cleanly. Score above neutral. The TBI use case requires careful pressure-tier selection, supervised protocol, and realistic expectation about partial response. Soft-chamber 1.3 ATA does not inherit hard-chamber TBI evidence.
Cellular Senescence: 5.7/10
Score: 5.7/10Hachmo 2020 supports reductions in immunosenescent blood cells after sixty hard-chamber sessions in older adults. Replication and clinical-outcome linkage are missing. Score above neutral but below strong-recommend because the evidence ecosystem is narrow and commercially adjacent. Healthy younger users should not expect senescence-clearance benefits comparable to a senolytic protocol. The cellular-senescence use case is real but expensive and not yet linked to disease-prevention or healthspan endpoints. Treat it as hypothesis-generating.
Chronic Pain Management: 5.7/10
Score: 5.7/10Fibromyalgia and CRPS evidence support the chronic pain use case more than generic wellness slugs. Efrati 2015 reports tender-point reduction and quality-of-life gains after forty hard-chamber sessions. Niezgoda 2025 reviews CRPS evidence with cautious support. Score above neutral with strong protocol and patient-selection caveats. Soft-chamber 1.3 ATA protocols do not inherit hard-chamber chronic pain evidence. Patients with primary chronic pain should select chambers, pressures, and session counts that match the cited trials.
Stem Cell Support: 5.6/10
Score: 5.6/10Human and animal data support CD34-positive progenitor mobilization after HBOT. Thom 2006 documents stem and progenitor mobilization with hyperbaric exposure. Heyboer 2014 extends similar findings. Wound recruitment is the most defensible stem-cell-relevant context. Do not frame hyperbaric oxygen as a stem-cell therapy. Score above neutral. Patients pursuing regenerative medicine should match progenitor mobilization framing to wound-healing or radiation-injury contexts rather than to general anti-aging marketing.
Neuroprotection: 5.3/10
Score: 5.3/10HBOT has plausible neuroplasticity, perfusion, and hypoxia-rescue mechanisms. Efrati 2013 supports chronic post-stroke neurorehab improvements with hard-chamber protocols. Neuroprotection as primary prevention is less established than post-injury rehabilitation. Score modestly above neutral because the most defensible framing is rescue and recovery rather than pre-emptive brain protection. Healthy users seeking neuroprotection have higher-evidence levers in sleep, exercise, cardiovascular control, and metabolic health.
Healthspan: 5.2/10
Score: 5.2/10Cognitive aging and telomere or senescence findings justify a small positive healthspan signal. Hachmo 2020 supports immunosenescence reduction in older adults. Hadanny 2020 supports cognitive gains in the same population. Clinical healthspan endpoints like disease-free survival or independent-living years remain unproven. Score modestly above neutral. The healthspan use case is hypothesis-generating, expensive, and protocol-heavy. Wealthy older adults with documented cognitive complaints are the most defensible candidate population.
Nerve Regeneration: 5.0/10
Score: 5.0/10Support is plausible through injury repair, CRPS, radiation injury, and neurorehab studies. Kiralp 2004 reports CRPS pain and function gains after a small RCT of hyperbaric oxygen. Direct peripheral nerve regeneration outcomes are less mature. Score at neutral-positive rather than high. Patients with peripheral neuropathy should match indication, etiology, and protocol carefully before assuming nerve-regeneration benefit. Diabetic peripheral neuropathy alone is not a strong indication for routine HBOT.
| Use Case | Score | Summary |
|---|---|---|
| ⚖️ Longevity / Lifespan Primary | 4.9 | Hachmo 2020 should be treated as hypothesis-generating because of methodological critique and financial conflicts. No authority body endorses HBOT as an anti-aging intervention. |
| ⚖️ Eye / Vision Health | 4.9 | Vision is mixed for HBOT. Central retinal artery occlusion appears on some indication lists, but transient myopia and cataract concerns are common adverse-event issues. Zhang 2023 documents adverse-event rates including vision changes during long protocols. Keep the score near neutral unless the report has a specific acute retinal indication. Long protocols benefit from periodic acuity checks. The eye-vision use case carries both narrow benefit and real safety considerations. |
| ⚖️ Endurance / Cardio | 4.9 | Middle-aged athlete data support oxygen utilization and mitochondrial endpoints. Hadanny 2022 reports mitochondrial respiration and performance gains. Amoako 2021 finds mixed timing-dependent recovery effects in a sports meta-analysis. Broad endurance improvements remain inconsistent across athletic populations. Keep score near neutral. Endurance athletes targeting performance should not displace volume, intensity, sleep, and nutrition with hyperbaric sessions. Soft-chamber protocols at 1.3 ATA do not inherit hard-chamber athletic evidence. |
| ⚖️ Energy / Fatigue | 4.8 | Some users report energy improvements after full protocols, especially with fatigue syndromes, but Kjellberg 2025 weakens short-course long-COVID fatigue expectations. |
| ○ Cardiovascular | 4.7 | HBOT has vascular and angiogenic mechanisms with small evidence in peripheral ischemia and erectile function. It is not a general cardiovascular prevention tool. Hadanny 2018 supports vascular endothelial effects in selected patients but does not extend to primary prevention. Score below 5 because the cardiovascular use case is best framed as ischemic tissue rescue, not background heart-health optimization. Healthy users should not expect lipid, blood-pressure, or atherosclerosis benefit from a hyperbaric protocol. |
| ○ VO2 Max | 4.7 | Hadanny 2022 supports physical performance gains in middle-aged athletes after hard-chamber protocols. VO2 max specifically is not established enough to score high across users. Healthy endurance athletes should not expect HBOT to substitute for periodized training, altitude exposure, or interval work. Score below neutral. The VO2 max use case is plausible but inconsistently demonstrated. Soft-chamber protocols at 1.3 ATA do not inherit hard-chamber athletic evidence and should not anchor a VO2 claim. |
| ○ Immune Function | 4.6 | HBOT affects immune cell senescence, cytokine balance, infection biology, and wound defense. Hachmo 2020 reports lower senescent immune-cell fractions after sixty hard-chamber sessions in older adults. Benson 2003 documents acute immune cell shifts after hyperbaric exposure. Broad immune-function enhancement remains unproven. Use moderate mechanistic language and avoid framing HBOT as a general immune booster. Indication-specific infection contexts retain stronger support than wellness immune claims. |
| ○ Skin / Beauty | 4.6 | Wound healing and radiation-injured tissue support skin repair, but beauty and anti-aging skin claims are weaker than medical wound care. Yang 2024 supports adjunctive wound healing in selected patients. Cosmetic skin rejuvenation, collagen optimization, or anti-wrinkle marketing exceeds the evidence. Keep below five unless the use case is documented wound or graft-flap context. Soft-chamber facial protocols sold as anti-aging are far weaker than hard-chamber wound trials. |
| ○ Mood / Emotional Regulation | 4.6 | Mood improvements appear as secondary outcomes in post-COVID, fibromyalgia, TBI, and PTSD-adjacent literature. Zilberman-Itskovich 2022 reports secondary mood gains within a sham-controlled long-COVID trial. Mood is not a primary established indication for HBOT. Score below neutral because mood gains are usually downstream of pain, fatigue, or cognitive improvements rather than direct mood mechanism. Patients with primary depression or anxiety should not pursue hyperbaric oxygen as a first-line mood treatment. |
| ○ Acute Pain Relief | 4.4 | Acute pain may improve in injury, burn, or CRPS-related contexts where hyperbaric exposure reduces inflammation and supports tissue oxygenation. Kiralp 2004 reports CRPS pain and function changes. HBOT is not a primary acute analgesic and does not substitute for standard acute pain care. Score below neutral. The acute-pain use case is narrow, indication-specific, and dependent on supervised access early after injury. |
| ○ Libido / Sexual Health | 4.4 | Erectile function evidence appears vascular and angiogenic rather than broad libido modulation. Hadanny 2018 reports vascular endothelial gains with HBOT. Score modestly and avoid implying hormonal libido enhancement. Patients with vascular erectile dysfunction may have a narrow indication context, but lifestyle, cardiovascular control, and clinician-managed pharmacology remain first-line. Healthy users seeking libido optimization should not expect benefit from hyperbaric oxygen at any pressure tier. The libido use case stays below neutral. |
| ○ Metabolic Health | 4.3 | Diabetic wound-care evidence is strong, and reviews suggest HBOT can affect glucose handling acutely. McIntosh 2021 documents intra-session glucose changes in patients with diabetes. This does not make hyperbaric oxygen therapy a metabolic-health treatment. Healthy users seeking insulin sensitivity or weight gains should not expect benefit. Keep the score modest because metabolic improvements are downstream of indication-specific care, not a primary metabolic mechanism. Better metabolic levers exist for prevention work. |
| ○ Anxiety | 3.9 | Anxiety can improve secondarily in TBI, PTSD, or post-COVID cohorts. Harch 2011 reports anxiety reduction in a post-concussion case series. Evidence is not strong enough to score anxiety as a primary HBOT indication. Patients with primary anxiety disorders should pursue evidence-based psychotherapy, exercise, sleep work, and clinician-led pharmacology before considering off-label hyperbaric protocols. Score below neutral to reflect the indirect and comorbid nature of the anxiety signal. |
| ○ Depression | 3.9 | Depression symptom improvements occur in some neurorecovery cohorts. Harch 2011 documents symptom reductions after post-concussion HBOT protocols. Evidence is indirect, comorbid, and small. Do not score HBOT as a primary depression intervention. Patients with major depressive disorder should pursue evidence-based therapy, exercise, sleep work, light exposure, and clinician-managed pharmacology. The depression use case stays below neutral. Hyperbaric oxygen is not a reliable first-line or second-line treatment for primary mood disorders. |
| ○ Sleep Quality | 3.8 | Sleep improvement may occur indirectly through pain reduction, fatigue improvement, or recovery effects. It is not a primary high-confidence HBOT endpoint. |
| ○ Gut Health / Microbiome | 3.8 | HBOT has small signals in fistulizing Crohn disease and inflammatory bowel contexts. Dulai 2012 reports adjunctive benefit in selected patients, but the evidence is heterogeneous and far from microbiome-grade. Broad gut-health or microbiome optimization claims are not supported. Keep below neutral unless the report is specifically discussing fistulizing Crohn disease as off-label adjunctive care under specialist supervision. General digestion, IBS, or leaky-gut framing is not a fit for HBOT. |
| ○ Strength / Power | 3.7 | Athlete RCTs show mitochondrial and performance signals in narrow cohorts. Hadanny 2022 reports performance and mitochondrial endpoint changes in middle-aged athletes. Strength and power outcomes are not consistently established. Healthy lifters and power athletes should not expect HBOT to substitute for resistance training, recovery, or nutrition. Score below neutral because pure strength and power evidence is thin and protocol-dependent. The general endurance side of athletic data is stronger than the strength-power side. |
| ○ Blood Sugar / Glycemic Control | 3.6 | HBOT may shift glucose during treatment in patients with diabetes, making monitoring important. McIntosh 2021 reviews intra-session glycemic effects. Evidence does not support using hyperbaric oxygen as primary glycemic control. The practical implication is safety screening and pre-session glucose checks for diabetic users on insulin or sulfonylureas. The blood-sugar use case stays below neutral because controlled trials do not show durable glycemic benefit beyond standard diabetes care. |
| ○ Antioxidant / Oxidative Stress | 3.6 | HBOT increases oxidative stress acutely and may upregulate antioxidant defenses. Leveque 2023 documents increased ROS and adaptive antioxidant response after hyperbaric exposure. Muth 2004 documents oxidative stress markers. The use case is hormetic rather than purely antioxidant. Score modestly and explicitly mention the oxidative stress paradox. Patients on high-pressure protocols may benefit from antioxidant cofactors. Routine antioxidant supplementation is not universally required for clinical HBOT. |
| ○ Stress / Resilience | 3.5 | PTSD and post-concussion studies contain stress-relevant signals, but general stress-resilience claims exceed the evidence. Weaver 2024 reports symptom changes in selected post-concussion populations. Keep below neutral unless the use case is tied to clinically diagnosed PTSD or TBI protocol. Healthy users seeking general stress-resilience improvements have stronger options in breathwork, cardiovascular fitness, sleep regularity, and HRV biofeedback. Hyperbaric oxygen is not a stress-resilience optimization tool. |
| ○ Reaction Time / Coordination | 3.4 | Cognitive processing speed improved in older adults per Hadanny 2020. Reaction-time and coordination are not established primary endpoints. Score below neutral because the reaction-time use case is best supported indirectly through processing-speed gains in aging cohorts. Healthy young users seeking reaction-time gains have stronger evidence-based options in sport-specific drills, sleep, and stimulant management. The reaction-time slug should not be sold as a hyperbaric performance feature. |
| ○ Respiratory | 3.2 | HBOT is not a lung-performance intervention. Oxygen toxicity and pneumothorax risk are central contraindication issues per Cooper 2026. Score low despite the oxygen delivery framing, because lung disease can increase risk rather than benefit. Patients with COPD bullae, asthma, or recent pulmonary infection need medical screening before any pressure exposure. The respiratory use case is best read as a safety-flag slot, not a wellness optimization opportunity. |
| ○ Pediatric Use | 3.0 | Pediatric medical indications exist in specialist care contexts. Autism and general pediatric neurodevelopment claims are weak and controversial. Rossignol 2009 reports short-term behavioral changes that have not held up in later reviews. Score below neutral because the pediatric use case is dominated by off-label autism marketing rather than supported pediatric care. Pediatric burn, severe infection, or carbon monoxide poisoning are narrow rescue contexts. Pediatric specialist supervision is required. |
Frequently Asked Questions
Is mild HBOT at 1.3 ATA the same as hard-chamber HBOT at 2.0-2.4 ATA?
No. Soft-chamber mild HBOT at 1.3-1.5 ATA and hard-chamber HBOT at 2.0-2.4 ATA should not be treated as the same intervention. The studies most often cited for cognitive aging (Hadanny 2020), fibromyalgia (Efrati 2015), and chronic post-stroke recovery (Efrati 2013) used hard-chamber pressure around 2.0 ATA. Soft chambers may be biologically active, but they do not reproduce the pressure tier behind those outcomes.
Is the $50,000+ Aviv Clinics protocol worth it for cognitive aging?
Only for a narrow buyer: older adult, documented cognitive complaint, enough budget that the cost does not displace higher-return basics, and realistic expectations about retreatment. Hadanny 2020 is the core cognitive-aging study, but it is not the same as broad preventive-medicine endorsement. The same commercial cluster also produced the telomere paper (Hachmo 2020), which should be treated cautiously because of methodological critique and financial conflicts.
Has the HBOT telomere lengthening study been replicated?
No independent replication is strong enough to treat telomere lengthening as established. Hachmo 2020 is interesting, but the study is small, commercially adjacent, and methodologically disputed. Use it as a hypothesis-generating signal, not as proof that HBOT reverses aging. The v1.0 rating therefore keeps longevity below the medical-indication scores.
Does HBOT help mild traumatic brain injury or post-concussion syndrome?
The evidence is contested. Some reviews and protocols argue benefit, and Shahid 2025 reports neurocognitive improvements across a small meta-analysis. But major military and guideline interpretations have been skeptical for persistent post-concussion symptoms, partly because sham-control design is difficult at low pressure. The large NCT06581003 veterans trial is the type of study that could materially change the score.
Is a home soft-chamber unit worth buying?
For generic longevity or cognitive-aging buyers, usually no. Home soft chambers are expensive, usually capped around 1.3-1.5 ATA, and do not match the hard-chamber pressure used in the main cognitive-aging, fibromyalgia, or post-stroke evidence. They may still be useful under clinician supervision for specific recovery contexts, but the marketing often outruns the evidence. If the target outcome requires 2.0 ATA evidence, a soft chamber is not a cheaper version of the same protocol.
Why is bleomycin chemotherapy a major contraindication?
Bleomycin exposure can create dangerous pulmonary toxicity under high-oxygen conditions. Hyperbaric programs commonly require specialist clearance, pulmonary function review, and a conservative washout approach before considering treatment. Doxorubicin, cisplatin, and disulfiram are also commonly flagged. This is why HBOT should be medically screened rather than treated like a spa oxygen session.
Does HBOT help long COVID?
The evidence is now mixed and less attractive than the older narrative. Hadanny 2024 supports persistence of improvements after a prior long-COVID HBOT protocol, but Kjellberg 2025 found 10 sessions were not superior to sham at 13 weeks on the primary RAND-36 physical function and role-physical outcomes. That does not prove no patient can benefit. It does mean short-course long-COVID HBOT should not be sold as established.
What are the most common side effects?
Ear barotrauma is the practical big one, followed by sinus pressure, claustrophobia, temporary myopia, fatigue after sessions, and rare oxygen toxicity seizures. Risk rises with higher pressure, longer sessions, poor equalization, upper-respiratory infection, and weak clinic protocols. Medical screening matters because untreated pneumothorax, COPD bullae, certain chemo exposures, and unstable glucose can turn a routine session into a serious problem.
Who is HBOT best for?
Best fit is a patient with a recognized medical indication or a tightly matched off-label condition under clinician supervision. Examples include decompression sickness, carbon monoxide poisoning, selected hard-to-heal wounds, delayed radiation injury, refractory osteomyelitis, compromised grafts/flaps, sudden sensorineural hearing loss, chronic post-stroke deficits (Efrati 2013), and fibromyalgia (Efrati 2015). Worst fit is a healthy budget-limited user buying soft-chamber sessions for vague anti-aging.
Is a soft-shell HBOT chamber the same as medical-grade HBOT?
No. Most clinical HBOT evidence uses hard chambers around 2.0 to 2.4 ATA with medical oxygen and trained supervision. Soft-shell mild HBOT usually runs around 1.3 to 1.5 ATA. Soft-shell protocols should not inherit hard-chamber evidence from cognitive-aging, fibromyalgia, post-stroke, post-COVID, wound, or radiation trials. The study pressure tier must match. UHMS 2023 warns that low-pressure fabric chambers below clinical thresholds lack reliable evidence below 1.4 ATA.
How many HBOT sessions does it usually take to see a clinical effect?
The strongest off-label neuro, pain, and aging protocols usually use 40 to 60 sessions. Fibromyalgia, chronic stroke, post-COVID, and chronic TBI studies commonly used 40 sessions. The Hachmo 2020 telomere and senescence aging protocol used 60 sessions. A 10-session long-COVID protocol was not clearly superior to sham in HOT-LoCO per Kjellberg 2025. Cash pricing commonly lands at $150 to $450 per session. A 40 to 60 session protocol totals $6,000 to $27,000 before travel.
Does higher ATA always mean better HBOT results?
No. Higher pressure can raise tissue oxygen exposure and may be required for some clinical protocols. It also raises adverse-event risk. Zhang 2023 found more adverse effects above 2.0 ATA and with more than 10 sessions. Ear discomfort was the most frequent adverse effect. Clinical protocols use indication-specific pressure, session length, and air breaks. The goal is balancing therapeutic oxygen signaling against barotrauma and oxygen-toxicity risk per Cooper 2026.
What should I verify before buying a large HBOT package?
Verify chamber type, ATA, oxygen source, air-break protocol, medical screening, emergency procedures, and fire-control practices. Confirm staff credentials and contraindication screening for pneumothorax, COPD bullae, and seizure history. Confirm your target outcome matches studies using that pressure tier. Ask how ear barotrauma, glucose instability, claustrophobia, vision changes, and oxygen-toxicity symptoms are handled. Avoid clinics selling hard-chamber outcomes from low-pressure soft-shell protocols. FDA 2025 has issued guidance on safe-use practices.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| NCT06581003 veterans TBI trial reads positive | Efficacy 3.7 to 4.2; Evidence 3.5 to 4.0; Bioindividuality 3.8 to 4.1 | 5.9 / 10 👍 Worth trying |
| Independent replication confirms Hachmo 2020 telomere finding | Evidence 3.5 to 4.2; Efficacy 3.7 to 4.0; Durability 3.0 to 3.5 | 5.8 / 10 👍 Worth trying |
| HOT-POCS reads strongly positive at 2.0 ATA | Efficacy 3.7 to 4.0; Evidence 3.5 to 4.0 | 5.6 / 10 👍 Worth trying |
| Three independent meta-analyses confirm cognitive-aging effect | Efficacy 3.7 to 4.2; Evidence 3.5 to 4.3 | 5.8 / 10 👍 Worth trying |
| Major chamber-fire cluster plus FDA crackdown on off-label use | Safety 4.0 to 4.5; Cost 4.5 to 4.8 | 4.6 / 10 ⚖️ Neutral |
| HOT-POCS reads negative plus another long-COVID sham trial is negative | Efficacy 3.7 to 3.2; Evidence 3.5 to 3.0 | 4.6 / 10 ⚖️ Neutral |
Key Evidence Sources
- Kjellberg A et al. 2025 - Ten sessions of hyperbaric oxygen versus sham treatment in patients with long covid (HOT-LoCO): a randomised, placebo-controlled, double-blind, phase II trial, BMJ Open. n=80 randomized; 10 sessions were not superior to sham at 13 weeks for RAND-36 physical functioning or role-physical; harms broadly similar
- Li et al. 2025 - The effect of acupuncture combined with hyperbaric oxygenation compared with hyperbaric oxygenation alone for patients with traumatic brain injury: a systematic review and meta-analysis, Frontiers in Neurology. 11 RCTs, 896 participants; combination therapy outperformed hyperbaric oxygenation alone on GCS, but methodological confidence was very low
- Li et al. 2024 - Efficacy and safety of hyperbaric oxygen therapy in acute ischaemic stroke: a systematic review and meta-analysis, BMC Neurology. 8 RCTs, 493 patients; did not support routine HBOT for acute ischemic stroke clinical outcomes
- Dokmak A et al. 2024 - Efficacy and Safety of Hyperbaric Oxygen Therapy in Fistulizing Crohn's Disease: A Systematic Review and Meta-analysis, Journal of Clinical Gastroenterology. 16 studies, 164 patients; pooled response/remission favorable but risk of bias and need for RCTs
- Yang et al. 2024 - Adjunctive hyperbaric oxygen therapy and negative pressure wound therapy for hard-to-heal wounds: a systematic review and meta-analysis, Journal of Wound Care. 15 studies; NPWT plus HBOT associated with better wound-healing rate than NPWT alone
- Shahid et al. 2025 - Hyperbaric oxygen therapy (HBOT) for neurocognitive deficits following traumatic brain injury: a systematic review and meta-analysis, Annals of Medicine & Surgery. 4 studies, 250 patients; reported neurocognitive improvements, with larger standardized trials needed
- Efrati S et al. 2015 - Hyperbaric Oxygen Therapy Can Diminish Fibromyalgia Syndrome - Prospective Clinical Trial, PLOS ONE. Prospective active-control crossover trial; favorable direction for fibromyalgia symptoms, quality of life, and brain SPECT activity
- Efrati S et al. 2013 - Hyperbaric Oxygen Induces Late Neuroplasticity in Post Stroke Patients - Randomized, Prospective Trial, PLOS ONE. Chronic post-stroke trial; favorable neurological function and quality-of-life direction after HBOT
- Hadanny A et al. 2024 - Long term outcomes of hyperbaric oxygen therapy in post covid condition: longitudinal follow-up of a randomized controlled trial, Scientific Reports. Long-term follow-up of a different post-COVID HBOT trial; not the HOT-LoCO 2025 sham-controlled RCT
- Hadanny A et al. 2020 - Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial. Older-adult cognitive-aging RCT using hard-chamber 2.0 ATA x 60-session protocol
- Hachmo Y et al. 2020 - Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial. Telomere and senescent-cell signal; treated here as under-replicated and methodologically contested
- Harch PG et al. 2022 - Hyperbaric oxygen therapy in chronic traumatic brain injury: perspective and dose discussion. Argues low-pressure sham arms may be active; useful for interpreting TBI controversy but not decisive efficacy proof
- Frontiers in Medicine 2023 - Adverse effects of hyperbaric oxygen therapy: systematic review. Side-effect review; ear barotrauma, pressure threshold effects, and pressure-related risk patterns
- Lin et al. 2023 - Hyperbaric oxygen therapy for late radiation tissue injury, Cochrane Database of Systematic Reviews. Indication-specific Cochrane support for late radiation tissue injury, not broad wellness endorsement
- ClinicalTrials.gov 2024 - Hyperbaric Oxygen Therapy for Persistent Post-Concussion Symptoms (HOT-POCS), NCT05643482. Protocol-stage evidence; pending trial relevant to post-concussion scoring
- ClinicalTrials.gov 2024 - Hyperbaric Oxygen Therapy in Veterans With TBI, NCT06581003. Large pending veterans TBI trial that could materially change efficacy and evidence scores
- Undersea and Hyperbaric Medical Society - Hyperbaric Oxygen Therapy indications and practice standards. Authority source for accepted clinical indications and facility/practice framing
- U.S. Food and Drug Administration - Hyperbaric oxygen therapy: don't be misled. FDA consumer framing distinguishing cleared uses from promoted unapproved uses and safety concerns
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Kjellberg 2025, Li 2025, Li 2024, Dokmak 2024, Yang 2024, Shahid 2025, Efrati 2015, Efrati 2013, Hadanny 2024, Hadanny 2020
Pre-RCT-Era Pharmacology and Use
Confidence: High
Citations: Haldane 1895, Behnke 1937, Churchill-Davidson 1955, UHMS 1967, FDA 2023
Traditional Medicine Systems
Confidence: Low
Citations: Priestley 1774, Lavoisier 1777, Beddoes 1794, Haldane 1895, Boerema 1960
Holistic Evidence for Hyperbaric Oxygen Therapy
All lenses converge on a narrow conclusion: HBOT is powerful when the target problem is pressure- and oxygen-responsive, but weak as a generic wellness abstraction. Modern evidence supports defined medical indications and selected off-label cohorts, while recent long-COVID and acute-stroke evidence forces more caution. History supports clinical hyperbaric medicine as a disciplined specialty with strict safety protocols. Traditional evidence adds little. The honest synthesis is indication-first, hard-chamber-first, medically supervised, and skeptical of soft-chamber anti-aging extrapolation.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Oxygen Saturation Baseline (pre-protocol)
- hs-CRP During | Expected Down
- Hemoglobin During | Expected Stable
- Hematocrit During | Expected Stable
- 8 Ohdg During | Expected Watch
- F2 Isoprostanes During | Expected Watch
- Oxidized LDL During | Expected Watch
- Gsh Gssg Ratio During | Expected Watch
- Sod Activity During | Expected Up
- Glutathione During | Expected Stable
- Il 6 During | Expected Down
- Tnf Alpha During | Expected Down
- Fibrinogen During | Expected Down
- Telomere Length Baseline (pre-protocol)
- Cd28 Negative T Cells Baseline (pre-protocol)
- Vegf During | Expected Watch
- Nitric Oxide Metabolites During | Expected Up
- Glucose Fasting Baseline (pre-protocol) During | Expected Watch
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Body During | Expected Up | Primary
- Calm During | Expected Up | Secondary
Subjective Signals (Daily Voice Card)
- Ear Pressure Scale 1-5 | During | Expected Watch
- Cognitive Clarity Scale 1-5 | During | Expected Up
- Fatigue After Session Scale 1-5 | During | Expected Watch
- Attention (cognitive battery) Scale 1-5 | During | Expected Up
- Processing Speed (cognitive battery) Scale 1-5 | During | Expected Up
- Executive Function (cognitive battery) Scale 1-5 | During | Expected Up
- Memory (cognitive battery) Scale 1-5 | During | Expected Up
- Vision Acuity Check (after 20 sessions) Scale 1-5 | During | Expected Watch
- Protocol Fidelity (ATA + minutes + air breaks) Scale 1-5 | During | Expected Stable
- Chamber Type (hard vs soft) and Total Sessions Scale 1-5 | Baseline (pre-protocol)
Red Flags: Stop and Consult
- Ear or sinus barotrauma
- Vision changes
- Oxygen toxicity symptoms or seizure
- Inability to equalize ear pressure
- Hypoglycemia symptoms during or after session
- Pulmonary symptoms suggesting oxygen toxicity
Other interventions for Wound Healing
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.815 − 2.606 = 0.209
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.209 / 5) × 5 = 5.2 / 10
